Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CRT is more effective than oral minoxidil alone for treating hair loss.

This report presents the first successful management of minoxidil toxicosis in a cat, detailing the clinical progression and treatment plan used to resolve the condition.

This study found that inhibiting mTORC1 activity with rapamycin significantly increased melanin production and extended hair growth phase in human hair follicles, suggesting potential for managing hair growth and pigmentation disorders.

Minoxidil solution used on the scalp did not lower blood pressure in patients without hypertension.

This study investigated adverse events from low-dose systemic minoxidil in an older population with hair loss and found that 19% experienced mainly facial and body hypertrichosis, managed with interventions like dose reduction and diuretics; no serious adverse events occurred.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

Miliacin may help prevent hair loss and improve hair growth in mice with a condition similar to human baldness.

This abstract reports that topical minoxidil is currently the only FDA-approved treatment for pattern hair loss in both men and women.

This study found that 2.2% minoxidil gel was more effective than placebo in treating alopecia areata and reported similar safety outcomes between the two groups.

In this study, researchers developed a fast-dissolving microneedle patch delivering minoxidil nanoparticles and plant-derived vesicles, which improved hair regrowth and follicle health in a mouse model of androgenetic alopecia by reducing oxidative stress and inflammation without causing skin irritation or systemic toxicity.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study described a novel three-dimensional-printed microneedle system designed for improved transdermal delivery of minoxidil to treat hair loss, demonstrating effective hair regrowth and safety in a mouse model while allowing sustainable needle base recovery.

This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.

This review discusses the management of recurrent ischemic priapism, highlighting that various treatments show differing efficacy and side effect profiles but that more research is needed to refine these strategies.

This study found that miR-150 enhances the resolution ability of endothelial progenitor cells in venous thrombosis by promoting cell differentiation and proliferation through specific gene regulation pathways.

Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This study found that topical minoxidil significantly increased terminal hair growth in men with early male pattern baldness compared to placebo over a 4-month period.

Minoxidil is commonly used for female hair loss, with other treatments being explored.

Minoxidil is commonly used for female hair loss, with other treatments being explored.

This study reports that topical 5% minoxidil solution significantly increased total hair counts and hair diameter in Korean men with androgenetic alopecia over 24 weeks and was well tolerated.

Combining minoxidil and PRP is more effective for hair growth than using either alone.

This study suggests that minoxidil is a potent stimulator of elastin expression in embryonic skin fibroblasts, primarily affecting elastin mRNA levels, without impacting cell proliferation during the stationary phase.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

This study found that adding platelet-rich plasma to 5% minoxidil treatment improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone.